Showing 681-690 of 9295 results for "".
Preserve the Core; Live Your Aesthetic
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/preserve-the-core-live-your-aesthetic/19083/Heidi Waldorf, MD, FAAD and Steven Dayan, MD, FACS, Co-Chief Medical Editors of Modern Aesthetics®magazine, talk about the importance of staying true to your aesthetic and address the challenges of preserving the core specialties.Antioxidants and Sunscreens
https://practicaldermatology.com/topics/skin-cancer-photoprotection/antioxidants-and-sunscreens--esapeged/19091/Jennifer Linder, MD, FAAD explains the science behind antioxidants in sunscreens and discusses the benefits of using antioxidants along with SPF.Sunscreen Water Seems All Washed Up; Fake Cosmeceuticals Raise Concerns
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-sunscreen-water-seems-all-washed-up-fake-cosmeceuticals-raise-concerns/19119/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine we take a look at drinkable sunscreen and school bans on sunscreens, get an update on Vegas Cosmetic Surgery, and meet the new face of AMBI skincare. Plus, our DermFocus investigates the problem of counterfeit cosHoya ConBio - Laser Assisted Hair Reduction
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/hoya-conbio-laser-assisted-hair-reduction/19461/Video demonstrations on the different settings to use for laser assisted hair reduction.New Clinical Guidelines for Nonmelanoma Skin Cancer Treatment; Arctics Biotherapeutics Seeks New FDA Approval for ZORYVE Foam
https://practicaldermatology.com/series/dermwire-tv/new-clinical-guidelines-for-nonmelanoma-skin-cancer-treatment-arctics-biotherapeutics-seeks-new-fda-approval-for-zoryve-foam/26745/In this week’s DermwireTV, new clinical guidelines for nonmelanoma skin cancer treatment; Arcutis Biotherapeutics seeks new FDA approval for ZORYVE foam; Practical Dermatology joins the ReachMD network; and the CEO of SofWave Medical joins us to discuss the company’s Ultrasound technology.Part 3, 1726 nm lasers: How to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is to be patient
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24341/Chapter 3 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about how to talk to patients about incorporating the 1726 nm wavelength lasers into their treatment regimens: Hint is toPart 4, 1726 nm lasers: Handling referred patients who are already on different treatment regimens
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24342/Chapter 4 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about handling referred patients who are already on different treatment regimens.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.Discover Dr Boswell’s Perspective: Redefining PN and AD Through a Neuroimmune Lens
https://practicaldermatology.com/programs/nemluvio-peer-network/discover-dr-boswells-perspective-redefining-pn-and-ad-through-a-neuroimmune-lens/56421/In this Clinical Conversations newsletter, Dr Scott Boswell shares how reframing prurigo nodularis (PN) and atopic dermatitis (AD) as neuroimmune-driven conditions has shaped his clinical philosophy. He shares his 3‑step approach to patient communication, highlights real‑world treatment journeys inFDA Approval for Delgocitinib
https://practicaldermatology.com/series/c-suite-chats/fda-approval-for-delgocitinib/36650/Robert Spurr, EVP, North America for LEO Pharma, discusses the importance of an FDA-approved option for treating moderate-to-severe chronic hand eczema in adults.